Observational, prospective study to examine association values of Interferon-Gamma Release Assay (IGRA) before and after treatment and clinical response or adverse events in patients with lung cancer who received cytotoxic cancer chemotherapy containing platinum with or without Immune Checkpoint Inhibitor (ICI)
Not Applicable
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000037308
- Lead Sponsor
- Osaka Prefectural Hospital Organization Osaka Habikino Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patient with synchronou or metachronous lung cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method